Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2019

View Archived Issues

CTI BioPharma presents data from dose-finding PAC203 study of pacritinib

UNC-0638 in combination with HRI knockdown leads to induction of fetal hemoglobin

Novel TRIM24(COE) mouse model of metaplastic TNBC

Bacterial peptides can be gluten lookalikes

Long-term follow-up data presented from phase IIa study of KD-025 in cGvHD

Promising preclinical data presented for the HER2-targeting engineered toxin body MT-5111

Phase II data presented for efgartigimod in adults with primary ITP

AC Immune patents alpha-synuclein-targeting compounds for PET imaging

Lack of genomic diversity means actionable mutations are left undiscovered

XW Laboratories discloses Exp1 receptor antagonists

BeiGene identifies new MAP4K1 inhibitors

Qingdao Marine Biological Medicine Research presents EGF and FGF inhibitors

Dybly describes new BRD4 inhibitors

Principia advances PRN-1008 for pemphigus with accelerated enrollment in phase III study

New phase Ib study evaluates mavorixafor with ibrutinib for Waldenstrom's macroglobulinemia

Hookipa begins dosing in phase I/II trial of HB-201 for HPV16-positive cancers

FDA approves OncoImmune's IND for anti-CTLA-4 antibody ONC-392

BioXcel begins phase III program with BXCL-501 for agitation in schizophrenia and bipolar disorder

CTX-712: a novel promising CLK inhibitor for myeloid tumors

Anthos Therapeutics studies MAA-868 in phase II for atrial fibrillation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...